Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.

ABSTRACT:

Background

Alzheimer's disease (AD) neuropathology is associated with neuroinflammation, but there are few useful biomarkers. Mutant variants of triggering receptor expressed on myeloid cells 2 (TREM2) have recently been linked to late-onset AD and other neurodegenerative disorders. TREM2, a microglial receptor, is involved in innate immunity. A cleaved fragment, soluble TREM2 (sTREM2), is present in the cerebrospinal fluid (CSF).

Methods

We developed and used a novel enzyme-linked immunosorbent assay to investigate the potential value of CSF sTREM2 as an AD biomarker in two independent cohorts: an AD/mild cognitive impairment (MCI)/control cohort (n = 100) and an AD/control cohort (n = 50).

Results

We found no significant difference in sTREM2 levels between groups of

SUBMITTER: Henjum K 

PROVIDER: S-EPMC4848774 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature